logo-loader
viewSareum Holdings PLC

Sareum Holdings says CEO, Dr Tim Mitchell to give on-line presentation at BIO Digital 2020

The presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively

Sareum Holdings PLC -
BIO Digital 2020 will be delivered on-line from June 8-12, 2020.

Sareum Holdings PLC (LON:SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, has announced that its CEO, Dr Tim Mitchell, will give a company presentation at BIO Digital 2020, which will be delivered on-line from June 8-12, 2020.

It said the presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively.

READ: Sareum Holdings agrees licensing deal with Shanghai-listed firm

Dr Mitchell will also outline the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections, the group added.

For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive participant's businesses, and the insights needed to continue critical research and development.

The presentation will be made through the BIO Digital website and will be available on-demand to registered participants during the conference: www.bio.org/events/bio-digital/sessions/685707

A copy of the presentation will also be made available on Sareum's website: www.sareum.co.uk.

The company also noted that its website has been updated to include information on the potential of its SDC-1801 TYK2/JAK1 inhibitor in the fight against coronavirus (COVID-19), which available at: www.sareum.com/discovery/tyk2jak1-covid19/

Quick facts: Sareum Holdings PLC

Price: 0.8 GBX

AIM:SAR
Market: AIM
Market Cap: £26.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read